{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:00:24Z","timestamp":1792069224579,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tchaikapharma High Quality Medicines Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:p>Hypertension is a complex syndrome of multiple hemodynamic, neuroendocrine, and metabolic abnormalities. The goals of treatment in hypertension are to optimally control high blood pressure and to reduce associated cardiovascular morbidity and mortality using the most suitable therapy available. Hydrochlorothiazide (HCTZ) and chlorthalidone (CTLD) are with proven hypertensive effects. The topic of our meta-analysis is to compare the efficacy of HCTZ and CTLD therapy in patient with hypertension. A search of electronic databases PubMed, MEDLINE, Scopus, PsyInfo, eLIBRARY.ru was performed. We chose the random-effects method for the analysis and depicted the results as forest plots. Sensitivity analyses were performed in order to evaluate the degree of significance of each study. Of the 1289 identified sources, only nine trials directly compared HCTZ and CTLD and were included in the meta-analysis. Changes in SBP lead to WMD (95% CI) equal to \u22123.26\u2009mmHg showing a slight but statistically significant prevalence of CTLD. Results from analyzed studies referring to DBP lead to WMD (95% CI) equal to \u22122.41\u2009mmHg, which is also statistically significant. During our analysis, we found that there were not enough studies presenting enough data on the effect of CTLD and HCTZ on levels of serum potassium and serum sodium. Our meta-analysis has demonstrated a slight superiority for CTLD regarding blood pressure control. At the same time, the two medications do not show significant differences in their safety profile.<\/jats:p>","DOI":"10.1038\/s41371-019-0255-2","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T09:02:50Z","timestamp":1570525370000},"page":"766-774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide\u2014meta-analysis"],"prefix":"10.1038","volume":"33","author":[{"given":"Stela","family":"Dineva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Uzunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velichka","family":"Pavlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Filipova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krassimir","family":"Kalinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Vekov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,8]]},"reference":[{"key":"255_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/archinte.1993.00410020005001","volume":"153","author":"MA Weber","year":"1993","unstructured":"Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993;153:149\u201352.","journal-title":"Arch Intern Med"},{"key":"255_CR2","doi-asserted-by":"crossref","unstructured":"Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure Group. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154\u201383.","DOI":"10.1001\/archinte.1993.00410020010002"},{"key":"255_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0895-7061(96)00323-8","volume":"10","author":"JL Pool","year":"1997","unstructured":"Pool JL, Cushman WC, Saini RK, Nwachuku CE, Battikha JP. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertens. 1997;10:117\u201323.","journal-title":"Am J Hypertens."},{"key":"255_CR4","unstructured":"Centers for Disease Control and Prevention. Hypertension. Adanta: Centers for Disease Control and Prevention; 2011. \nwww.cdc.gov\/nchs\/fastars\/hyprtens.htm\n\n. Accessed Dec 2011."},{"key":"255_CR5","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(08)60655-8","volume":"371","author":"CM Lawes","year":"2008","unstructured":"Lawes CM, Vander Hoorn S, Rodgers A.International Society of Hypertension Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513\u20138.","journal-title":"Lancet"},{"key":"255_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.7326\/0003-4819-158-6-201303190-00004","volume":"158","author":"IA Dhalla","year":"2013","unstructured":"Dhalla IA, Gomes T, Yao Z, Nagge J, Persaud N, Hellings C, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013;158:447\u201355. \nhttps:\/\/doi.org\/10.7326\/0003-4819-158-6-201303190-00004\n\n.","journal-title":"Ann Intern Med."},{"key":"255_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1161\/HYPERTENSIONAHA.110.161505","volume":"57","author":"MP Dorsch","year":"2011","unstructured":"Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689\u201394. \nhttps:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.161505\n\n.","journal-title":"Hypertension."},{"key":"255_CR8","unstructured":"Lamb E. Top 200 prescription drugs of 2008. Pharmacy Times. 2009. \nhttp:\/\/www.pharmacytimes.com\/issue\/pharmacy\/2009\/2009-05\/RxFocusTop200Drugs-0509\n\n."},{"key":"255_CR9","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1751-7176.2009.00166.x","volume":"11","author":"B Pitt","year":"2009","unstructured":"Pitt B. The role of chlorthalidone in patients with high-risk hypertension. J Clin Hypertens. 2009;11:460\u20131.","journal-title":"J Clin Hypertens."},{"key":"255_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1751-7176.2008.00009.x","volume":"11","author":"ME Ernst","year":"2009","unstructured":"Ernst ME, Carter BL, Basile JN. All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH Study into perspective. J Clin Hypertens. 2009;11:5\u201310.","journal-title":"J Clin Hypertens."},{"key":"255_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/ajh.2010.1","volume":"23","author":"ME Ernst","year":"2010","unstructured":"Ernst ME, Carter BL, Zheng S, Grimm RH Jr. Meta-analysis of dose response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens. 2010;23:440\u20136.","journal-title":"Am J Hypertens"},{"key":"255_CR12","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1517\/14656560903158956","volume":"10","author":"DA Sica","year":"2009","unstructured":"Sica DA. Chlorthalidone: a renaissance in use? Expert Opin Pharmacother. 2009;10:2037\u20139.","journal-title":"Expert Opin Pharmacother."},{"key":"255_CR13","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1161\/HYPERTENSIONAHA.109.135061","volume":"54","author":"NM Kaplan","year":"2009","unstructured":"Kaplan NM. The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide. Hypertension. 2009;54:951\u20133.","journal-title":"Hypertension."},{"key":"255_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","volume":"47","author":"ME Ernst","year":"2006","unstructured":"Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352\u20138.","journal-title":"Hypertension."},{"key":"255_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0002-9149(86)90232-8","volume":"58","author":"Multiple Risk Factor Intervention Trial Research Group.","year":"1986","unstructured":"Multiple Risk Factor Intervention Trial Research Group. Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the multiple risk factor intervention trial. Am J Cardiol. 1986;58:1\u201313.","journal-title":"Am J Cardiol."},{"key":"255_CR16","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1161\/01.CIR.82.5.1616","volume":"82","author":"Multiple Risk Factor Intervention Trial Research Group.","year":"1990","unstructured":"Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1\/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616\u201328.","journal-title":"Circulation."},{"key":"255_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1161\/01.HYP.0000203147.75714.ba","volume":"47","author":"DA Sica","year":"2006","unstructured":"Sica DA. Chlorthalidone: has it always been the best thiazide-type diuretic? Hypertension. 2006;47:321\u20132.","journal-title":"Hypertension"},{"key":"255_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/HYPERTENSIONAHA.110.156166","volume":"56","author":"TW Kurtz","year":"2010","unstructured":"Kurtz TW. Chlorthalidone: don\u2019t call it \u201cThiazide-Like\u201d anymore. Hypertension. 2010;56:335\u20137.","journal-title":"Hypertension"},{"key":"255_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/CRD.0b013e3181c61b52","volume":"18","author":"KM Neff","year":"2010","unstructured":"Neff KM, Nawarskas JJ. Hydrochlorothiazide versus chlorthalidone in the management of hypertension. Cardiol Rev. 2010;18:51\u20136.","journal-title":"Cardiol Rev."},{"key":"255_CR20","unstructured":"Steber CJ. Differences in chlorthalidone\u2019s mechanism of action vs hydrochlorothiazide and its clinical relevance. EBM Consult; 2015. \nhttps:\/\/www.ebmconsult.com\/articles\/chlorthalidone-hydrochlorothiazide-differences-mechanism-of-action#jump_ss_101115\n\n."},{"key":"255_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/hr.2012.143","volume":"36","author":"BJ Kwon","year":"2013","unstructured":"Kwon BJ, Jang SW, Choi KY, Kim DB, Cho EJ, Ihm SH, et al. Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-na\u00efve patients of hypertension. Hypertens Res. 2013;36:79\u201384. \nhttps:\/\/doi.org\/10.1038\/hr.2012.143\n\n.","journal-title":"Hypertens Res."},{"key":"255_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMoa021716","volume":"348","author":"LM Wing","year":"2003","unstructured":"Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting\u2014enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583\u201392.","journal-title":"N Engl J Med"},{"key":"255_CR23","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417\u201328.","journal-title":"N Engl J Med"},{"key":"255_CR24","doi-asserted-by":"publisher","first-page":"d4891","DOI":"10.1136\/bmj.d4891","volume":"343","author":"T Krause","year":"2011","unstructured":"Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.","journal-title":"BMJ"},{"key":"255_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1161\/HYPERTENSIONAHA.110.154476","volume":"56","author":"R Wood","year":"2010","unstructured":"Wood R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension. 2010;56:463\u201370.","journal-title":"Hypertension"},{"key":"255_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/jch.12453","volume":"17","author":"JJ Saseen","year":"2015","unstructured":"Saseen JJ, Ghushchyan V, Nair KV. Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population. J Clin Hypertens. 2015;17:134\u201340. \nhttps:\/\/doi.org\/10.1111\/jch.12453\n\n.","journal-title":"J Clin Hypertens."},{"key":"255_CR27","doi-asserted-by":"publisher","first-page":"1229.e1","DOI":"10.1016\/j.amjmed.2012.05.023","volume":"125","author":"GL Bakris","year":"2012","unstructured":"Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125:1229.e1\u20131229.e10. \nhttps:\/\/doi.org\/10.1016\/j.amjmed.2012.05.023\n\n.","journal-title":"Am J Med."},{"key":"255_CR28","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1517\/14656560902991514","volume":"10","author":"A Pareek","year":"2009","unstructured":"Pareek A, Basavanagowdappa H, Zawar S, Kumar A, Chandurkar N. A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25\u2009mg) combination with losartan-hydrochlorothiazide (12.5\u2009mg) combination in Indian patients with mild-to-moderate essential hypertension. Expert Opin Pharmacother. 2009;10:1529\u201336. \nhttps:\/\/doi.org\/10.1517\/14656560902991514","journal-title":"Expert Opin Pharmacother."},{"key":"255_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jacc.2015.10.083","volume":"67","author":"AK Pareek","year":"2016","unstructured":"Pareek AK, Messerli FH, Chandurkar NB, Dharmadhikari SK, Godbole AV, Kshirsagar PP, et al. Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol. 2016;67:379\u201389. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2015.10.083\n\n.","journal-title":"J Am Coll Cardiol."},{"key":"255_CR30","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.amjmed.2014.04.014","volume":"127","author":"JC van Blijderveen","year":"2014","unstructured":"van Blijderveen JC, Straus SM, Rodenburg EM, Zietse R, Stricker BH, Sturkenboom MC, et al. Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. Am J Med. 2014;127:763\u201371. \nhttps:\/\/doi.org\/10.1016\/j.amjmed.2014.04.014\n\n.","journal-title":"Am J Med."},{"key":"255_CR31","doi-asserted-by":"crossref","unstructured":"SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP).\u00a0 J Am Med Assoc. 1991;265:3255\u201364.","DOI":"10.1001\/jama.265.24.3255"},{"key":"255_CR32","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc. 2002;288:2981\u201397.","journal-title":"J Am Med Assoc"},{"key":"255_CR33","unstructured":"National Heart, Lung and Blood Institute, NIH. Systolic Blood Pressure Intervention Trial (SPRINT) overview. National Heart, Lung and Blood Institute; 2015. \nhttp:\/\/www.nhlbi.nih.gov\/news\/spotlight\/fact-sheet\/systolic-bloodpressure-intervention-trial-sprint-overview\n\n."},{"key":"255_CR34","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1524-6175.2004.03789.x","volume":"6","author":"DA Sica","year":"2004","unstructured":"Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens. 2004;6:532\u201340.","journal-title":"J Clin Hypertens."},{"key":"255_CR35","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1152\/ajplegacy.1975.228.4.1249","volume":"228","author":"RN Khuri","year":"1975","unstructured":"Khuri RN, Strieder WN, Giebisch G. Effects of flow rate and potassium intake on distal tubular potassium transfer. Am J Physiol. 1975;228:1249\u201361.","journal-title":"Am J Physiol."},{"key":"255_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.pa.26.040186.001453","volume":"26","author":"H Velazquez","year":"1986","unstructured":"Velazquez H, Wright FS. Control by drugs of renal potassium handling. Annu Rev Pharm Toxicol. 1986;26:293\u2013309.","journal-title":"Annu Rev Pharm Toxicol."},{"key":"255_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0002-9149(85)90290-5","volume":"55","author":"Multiple Risk Factor Intervention Trial Research Group.","year":"1985","unstructured":"Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the multiple risk factor intervention trial. Am J Cardiol. 1985;55:1\u201315.","journal-title":"Am J Cardiol."},{"key":"255_CR38","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1111\/jcmm.13205","volume":"21","author":"W Liang","year":"2017","unstructured":"Liang W, Ma H, Cao L, Yan W, Yang J. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. J Cell Mol Med. 2017;21:2634\u201342. \nhttps:\/\/doi.org\/10.1111\/jcmm.13205\n\n.","journal-title":"J Cell Mol Med."},{"key":"255_CR39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/ajh.2010.1","volume":"23","author":"ME Ernst","year":"2010","unstructured":"Ernst ME, Carter BL, Zheng S, Grimm RH Jr. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens. 2010;23:440\u20136. \nhttps:\/\/doi.org\/10.1038\/ajh.2010.1\n\n. Epub 2010 Jan 28.","journal-title":"Am J Hypertens."},{"key":"255_CR40","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/HYPERTENSIONAHA.111.190637","volume":"59","author":"MA Peterzan","year":"2012","unstructured":"Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59:1104\u20139. \nhttps:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.190637\n\n.","journal-title":"Hypertension."},{"key":"255_CR41","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1161\/HYPERTENSIONAHA.114.05021","volume":"65","author":"GC Roush","year":"2015","unstructured":"Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65:1041\u20136. \nhttps:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.05021\n\n.","journal-title":"Hypertension."}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41371-019-0255-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-019-0255-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41371-019-0255-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:24:17Z","timestamp":1684617857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-019-0255-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,8]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["255"],"URL":"https:\/\/doi.org\/10.1038\/s41371-019-0255-2","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,8]]},"assertion":[{"value":"11 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SD, VP, KU, and EF are the employees of Tchaikapharma High Quality Medicines Inc. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}